Pancreatic Cancer Research

ResearcherRoswell Park Comprehensive Cancer CenterNo recent work listed

Li Yan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4792-9998; OpenAlex author ID A5100653025. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2019: 1 paper · 2020: 4 papers · 2021: 4 papers · 2022: 1 paper · 2023: 2 papers

Papers 12

  1. A novel aging-associated lncRNA prognostic signature for predicting immunotherapy and chemotherapy response in pancreatic cancer Co-author DOI 10.21203/rs.3.rs-3431528/v1↗
  2. The Nomogram predicting the overall survival of patients with pancreatic cancer treated with radiotherapy: a study based on the SEER database and a Chinese coh… Co-author DOI 10.3389/fendo.2023.1266318↗
  3. Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-022-01384-3↗
  4. miR-194-5p down-regulates tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer. Co-author DOI 10.1016/j.intimp.2021.107822↗
  5. Annexin A1 Expression Is Associated with Epithelial-Mesenchymal Transition (EMT), Cell Proliferation, Prognosis, and Drug Response in Pancreatic Cancer. Co-author DOI 10.3390/cells10030653↗
  6. G2M checkpoint pathway alone is associated with drug response and survival among cell proliferation-related pathways in pancreatic cancer. Co-author PMID 34249445↗
  7. A prognostic score based on long-term survivor unique transcriptomic signatures predicts patient survival in pancreatic ductal adenocarcinoma. Co-author PMID 34659888↗
  8. miR-128 Regulates Tumor Cell CD47 Expression and Promotes Anti-tumor Immunity in Pancreatic Cancer. Co-author DOI 10.3389/fimmu.2020.00890↗
  9. Transcriptomic Profile of Lymphovascular Invasion, a Known Risk Factor of Pancreatic Ductal Adenocarcinoma Metastasis. Co-author DOI 10.3390/cancers12082033↗
  10. High G2M Pathway Score Pancreatic Cancer is Associated with Worse Survival, Particularly after Margin-Positive (R1 or R2) Resection. Co-author DOI 10.3390/cancers12102871↗
  11. A Novel Four-Gene Score to Predict Pathologically Complete (R0) Resection and Survival in Pancreatic Cancer. Co-author DOI 10.3390/cancers12123635↗
  12. Resistin effects on pancreatic cancer progression and chemoresistance are mediated through its receptors CAP1 and TLR4. First author DOI 10.1002/jcp.27631↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kazuaki Takabe · 6 shared papers, 2020–2021 · strength 0.85
  2. Masanori Oshi · 4 shared papers, 2020–2021 · strength 0.53
  3. Itaru Endo · 4 shared papers, 2020–2021 · strength 0.53
  4. Matthew H. G. Katz · 3 shared papers, 2020 · strength 0.37
  5. Eriko Katsuta · 2 shared papers, 2020–2021 · strength 0.33
  6. Qing Xi · 2 shared papers, 2020–2021 · strength 0.23
  7. Rongxin Zhang · 2 shared papers, 2020–2021 · strength 0.23
  8. Ling Yuan · 1 shared paper, 2023 · strength 0.19
  9. Bo Li · 1 shared paper, 2023 · strength 0.19
  10. Xiaotao Dong · 1 shared paper, 2023 · strength 0.19
  11. Yuling Chen · 1 shared paper, 2023 · strength 0.19
  12. Yuanchun Ye · 1 shared paper, 2023 · strength 0.19
  13. Ronghui Jin · 1 shared paper, 2019 · strength 0.14
  14. Min Zhang · 1 shared paper, 2019 · strength 0.14
  15. Hideo Takahashi · 1 shared paper, 2020 · strength 0.13
  16. Ying Chen · 1 shared paper, 2021 · strength 0.12
  17. Chengzhi Wang · 1 shared paper, 2021 · strength 0.12
  18. Wenhui Lou · 1 shared paper, 2022 · strength 0.11
  19. Yexin Tong · 1 shared paper, 2022 · strength 0.11
  20. Yuan Ji Ma · 1 shared paper, 2022 · strength 0.11
  21. Fan Zhang · 1 shared paper, 2022 · strength 0.11
  22. Chen Ding · 1 shared paper, 2022 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.